Last reviewed · How we verify
unchanged dose
The exact mechanism of unchanged dose is not well-documented.
The exact mechanism of unchanged dose is not well-documented. Used for Marketed for various uses.
At a glance
| Generic name | unchanged dose |
|---|---|
| Sponsor | Dunamenti REK Istenhegyi IVF Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Further research is needed to understand the underlying mechanism of unchanged dose.
Approved indications
- Marketed for various uses
Common side effects
Key clinical trials
- Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis (PHASE2)
- A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (PHASE1, PHASE2)
- Contextually Enriched Individualized Exercise Versus Contextually Fixed Exercise for Rotator Cuff-Related Shoulder Pain (NA)
- SPARK-ALL: Calaspargase Pegol in Adults With ALL (PHASE2, PHASE3)
- Neoadjuvant Chemoimmunotherapy or Chemoradiotherapy in ESCC (PHASE2)
- A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC (PHASE1, PHASE2)
- Eosinophil-guided Reduction of Inhaled Corticosteroids (PHASE4)
- Upadacitinib in Giant Cell Arteritis (GCA) With Active Large-vessel Involvement.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- unchanged dose CI brief — competitive landscape report
- unchanged dose updates RSS · CI watch RSS
- Dunamenti REK Istenhegyi IVF Center portfolio CI